|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administration_duration
|
1 hour
|
|
gptkbp:approves
|
gptkb:FDA
November 2020
|
|
gptkbp:associated_with
|
COVID-19 variants
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:can_be_combined_with
|
gptkb:Etesevimab
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
gptkb:Eli_Lilly_and_Company
Phase 2
Phase 3
improved recovery
reduced hospitalization
reduced emergency visits
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:contraindication
|
severe allergic reactions
hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
solution for infusion
700 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bamlanivimab
|
|
gptkbp:indication
|
mild to moderate COVID-19
|
|
gptkbp:invention
|
patented
|
|
gptkbp:market_position
|
hospital settings
available in pharmacies
|
|
gptkbp:marketed_as
|
gptkb:Bamlanivimab_injection
|
|
gptkbp:mechanism_of_action
|
neutralizes virus
neutralizes SARS-Co V-2
|
|
gptkbp:patient_population
|
adults
high-risk patients
pediatric patients
|
|
gptkbp:pharmacokinetics
|
Ig G1 monoclonal antibody
half-life 15 days
|
|
gptkbp:provides_guidance_on
|
WHO recommendations
CDC guidelines
|
|
gptkbp:publication
|
peer-reviewed journals
scientific articles
clinical trial reports
|
|
gptkbp:research_areas
|
pharmacology
infectious diseases
immunology
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_measures
|
post-marketing surveillance
adverse event tracking
clinical safety assessments
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
mandatory reporting
infusion reactions
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:suitable_for
|
severe COVID-19
|
|
gptkbp:targets
|
gptkb:SARS-Co_V-2
|
|
gptkbp:trade
|
gptkb:Bamlanivimab
|
|
gptkbp:used_for
|
gptkb:vaccine
treatment of COVID-19
|
|
gptkbp:bfsParent
|
gptkb:Lilly's_COVID-19_antibody_therapy
|
|
gptkbp:bfsLayer
|
5
|